AstraZeneca sells right to heart failure, blood pressure medicines for $400 million

(Reuters) – AstraZeneca Plc said on Friday it had agreed to sell commercial rights for two of its heart failure and blood pressure medicines to German pharmaceutical company Cheplapharm Arzneimittel GmbH for $400 million.

Under the deal, Cheplapharm will get commercial rights for Atacand and Atacand Plus in around 70 countries globally, AstraZeneca said.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Sriraj Kalluvila)